Hutchmed (China) Limited (HCM) ORD USD0.10

- Add to watchlist
- Create an alert
- This stock can be held in a




Share news, reports & tips
-
Hutchmed enrols patients for phase two savolitinib trial
22 April 2025 08:46
(Sharecast News) - Hutchmed China announced on Tuesday that it has completed patient enrollment for the registration phase of its phase two clinical trial, evaluating savolitinib in Chinese patients with...
-
Hutchmed renal cell carcinoma trial meets primary endpoint
19 March 2025 10:55
(Sharecast News) - Hutchmed China, alongside Innovent Biologics, announced on Wednesday that the FRUSICA-2 phase two and three clinical trial evaluating the combination of fruquintinib and sintilimab as a...
-
Hutchmed announces progress, hits milestone with lung cancer treatment
2 January 2025 15:30
(Sharecast News) - Hutchmed China announced a number of advancements on Thursday, including a regulatory milestone for its lung cancer treatment and a substantial divestment aimed at bolstering its core...
-
Hutchmed to receive $10m milestone payment from partner Takeda
13 December 2024 09:36
(Sharecast News) - Hutchmed China announced on Friday that it would receive a $10m milestone payment from its partner Takeda, following a national reimbursement recommendation for 'Fruzaqla', or...
-
Hutchmed lung cancer therapy gets breakthrough designation in China
12 December 2024 11:27
(Sharecast News) - Hutchmed China announced on Thursday that the Center for Drug Evaluation of China's National Medical Products Administration (NMPA) has granted breakthrough therapy designation (BTD)...
-
Hutchmed endometrial cancer treatment gets conditional approval in China
3 December 2024 10:14
(Sharecast News) - Hutchmed China and its partner Innovent Biologics announced conditional approval from China's National Medical Products Administration (NMPA) for the combination of...
-
Hutchmed partner launches Fruzaqla in Japan
22 November 2024 11:54
(Sharecast News) - Hutchmed China announced the launch of 'Fruzaqla', or fruquintinib, in Japan on Friday by its partner, Takeda, following approval from Japan's Ministry of Health, Labour and...
-
Hutchmed to receive $20m Fruzaqla milestone payment
31 October 2024 11:04
(Sharecast News) - Hutchmed China announced on Thursday that it was set to receive a $20m milestone payment from its partner Takeda, after sales of 'Fruzaqla', or fruquintinib, surpassed $200m.
-
Hutchmed reports positive results from AstraZeneca lung cancer collaboration
16 October 2024 11:41
(Sharecast News) - Hutchmed China announced positive results from its Savannah phase two trial on Wednesday, which studied the combination of 'Tagrisso', or osimertinib, and 'Orpathys',...
-
Hutchmed partner Takeda gets Japanese approval for Fruzaqla
24 September 2024 11:06
(Sharecast News) - Hutchmed China announced on Tuesday that its partner Takeda has received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) to manufacture and market...
-
Hutchmed to present new and updated clinical trial data
9 September 2024 12:31
(Sharecast News) - Hutchmed China has announced that it would present new and updated clinical trial data at two major oncology conferences - the 2024 World Conference on Lung Cancer (WCLC24) in San Diego,...
-
Hutchmed withdraws supplemental new drug application in China
30 August 2024 10:53
(Sharecast News) - Hutchmed China has voluntarily withdrawn its supplemental new drug application (NDA) in China for the use of fruquintinib in combination with paclitaxel for second-line treatment of...
Company announcements Announcements
-
HUTCHMED - Data to be Presented at AACR 2025
24 April 2025 07:00
HUTCHMED (China) Limited
-
HUTCHMED Completes Enrollment of Phase II Study
22 April 2025 07:00
HUTCHMED (China) Limited
-
2024 Annual Report and Notice of AGM
7 April 2025 09:30
HUTCHMED (China) Limited
-
Extraordinary General Meeting – Poll Results
31 March 2025 10:30
HUTCHMED (China) Limited
-
NMPA Conditional Approval for TAZVERIK®
21 March 2025 10:00
HUTCHMED (China) Limited
-
Retirement of Independent Non-executive Directors
20 March 2025 09:30
HUTCHMED (China) Limited
-
HUTCHMED Highlights Savolitinib SAVANNAH Phase II
20 March 2025 07:00
HUTCHMED (China) Limited
-
Publication of Form 20-F
19 March 2025 13:45
HUTCHMED (China) Limited
-
2024 Final Results and Business Updates
19 March 2025 11:00
HUTCHMED (China) Limited
-
Phase II/III Study of Fruquintinib and Sintilimab
19 March 2025 07:00
HUTCHMED (China) Limited
-
Vesting of awards under Long Term Incentive Plan
14 March 2025 09:30
HUTCHMED (China) Limited
-
Adoption of the 2025 Long Term Incentive Plan
14 March 2025 09:30
HUTCHMED (China) Limited
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2025. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.